Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Andreas Engstrom"'
Autor:
Margaret Hux, Denise Zou, Esprit Ma, Peter Sajosi, Andreas Engstrom, Ross Selby, Eugene Benson, Andrew Briggs, Vijayveer Bonthapally
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 4, Iss 2 (2016)
**Objective:** To evaluate the cost-effectiveness of brentuximab vedotin in patients with R/R sALCL from a UK NHS perspective. **Methods:** A partitioned survival model used clinical outcomes for brentuximab vedotin from the pivotal phase-2 single-a
Externí odkaz:
https://doaj.org/article/7d27a3d6afc843208c70026aeb5511d8
Autor:
Javaria Mona Khalid, Andreas Engstrom, Fabian Hoti, Jennifer Wall, Tobias Bäckström, Vasili Mushnikov, Gunnar Johansson
Publikováno v:
BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Pulmonary Medicine
BMC Pulmonary Medicine
Background Exacerbations of chronic obstructive pulmonary disease (COPD) are an important measure of disease severity in terms of impaired disease progression, increased recovery time, healthcare resource utilization, overall morbidity and mortality.
Autor:
Peter Sajosi, Vijayveer Bonthapally, Andrew Briggs, Bethan Sarah Woods, Ross Selby, James Eaton, Christopher Parker, Esprit Ma, Eugene Benson, Andreas Engstrom
Publikováno v:
941-837X
Objective: To evaluate cost-effectiveness of brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma who have received autologous stem cell transplantation, from a Scottish healthcare payer perspective. Methods: A Microsoft Excel-ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02047ec35d2baeecf367fd02cf12d088
https://eprints.whiterose.ac.uk/114013/1/Parker_Brentuximab_vedotin_cost_effectiveness_HL_manuscript_14_July_2016.doc
https://eprints.whiterose.ac.uk/114013/1/Parker_Brentuximab_vedotin_cost_effectiveness_HL_manuscript_14_July_2016.doc
Autor:
Andrew Briggs, Peter Sajosi, Jeremy Teasell, Vijayveer Bonthapally, Beth Woods, Akshara Richhariya, James Eaton, Andreas Engstrom, Eugene Benson, Chris Parker, Ross Selby, Esprit Ma, Gemma Kay
Publikováno v:
Journal of Clinical Oncology. 34:19-19
19 Background: In 2015, the Scottish Medicines Consortium (SMC) made a positive recommandation for brentuximab vedotin (BV) in patients with relapsed or refractory (R/R) Hodgkin lymphoma (HL) who have received autologous stem cell transplantation (AS
Autor:
Esprit Ma, Margaret Hux, Vijayveer Bonthapally, Jeremy Teasell, Ross Selby, Denise Zou, Akshara Richhariya, Peter Sajosi, Andreas Engstrom, Andrew Briggs, Eugene Benson
Publikováno v:
Journal of Clinical Oncology. 34:18-18
18 Background: Systemic anaplastic large cell lymphoma (sALCL) is a rare T-cell lymphoma. For patients who fail front-line therapy, outcomes are poor and there is no current defined standard of care. Brentuximab vedotin has demonstrated high objectiv
Autor:
Gunnar Johansson, Vasili Mushnikov, Tobias Bäckström, Andreas Engström, Javaria Mona Khalid, Jennifer Wall, Fabian Hoti
Publikováno v:
BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background Exacerbations of chronic obstructive pulmonary disease (COPD) are an important measure of disease severity in terms of impaired disease progression, increased recovery time, healthcare resource utilization, overall morbidity and m
Externí odkaz:
https://doaj.org/article/9cb74dfffa3245b4a1765b8eb6c4f165
Autor:
Denise Zou, Peter Sajosi, Andreas Engstrom, Selby Ross, Andrew Briggs, Vijayveer Bonthapally, Eugene Benson, Esprit Ma, Margaret Hux
Publikováno v:
Journal of Health Economics and Outcomes Research
Objective: To evaluate the cost-effectiveness of brentuximab vedotin in patients with R/R sALCL from a UK NHS perspective. Methods: A partitioned survival model used clinical outcomes for brentuximab vedotin from the pivotal phase-2 single-arm trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7888333335a17436467ea6f4f7723728
http://jheor.scholasticahq.com/article/9820-a-cost-effectiveness-analysis-of-brentuximab-vedotin-in-relapsed-or-refractory-systemic-anaplastic-large-cell-lymphoma.pdf
http://jheor.scholasticahq.com/article/9820-a-cost-effectiveness-analysis-of-brentuximab-vedotin-in-relapsed-or-refractory-systemic-anaplastic-large-cell-lymphoma.pdf